Pancreatic Adenocarcinoma
Conditions
Keywords
pancreas, quality of life, PRO, Pancreatic Adenocarcinoma
Brief summary
Due to the generally poor prognosis, with no chance of long-term survival, health related quality of life is a very important objective in the treatment of patients with pancreatic cancer. The non-interventional, prospective, multicentre PARAGON study is desinged to evaluate the health-related quality of life in patients with metastatic pancreatic cancer, by analyzing the course of QoL throughout all applied therapy lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome.
Detailed description
Pancreatic cancer is often diagnosed at an advanced stage, because most of the patients have no symptoms until the cancer metastasized. In the majority of study cases pancreatic cancer research focuses on therapy outcomes and prognosis. With poor prognosis and no chance of long-term survival, quality of life becomes a very significant purpose of pancreatic cancer care. The PARAGON study is designed to see a bigger picture by acquiring data on quality of life (QoL) and further outcome of patients with localized, locally advanced and metastatic pancreatic cancer and moreover to establish a sample collection for future biomarker analysis. The multicenter, prospective, permanent, register study PARAGON collects outcome data, patient reported outcomes (PRO), and tumor tissues of pancreatic cancer patients of both sexes and ages over 18 at approx. 80 German study sites. Patients diagnosed with pancreatic adenocarcinoma planned for (or recently started with) neoadjuvant, adjuvant or 1st line therapy can be included into the study. The data assessment includes data on demography, basic parameters, anamnesis, comorbidities, therapies, outcome and survival data as well as patient reported outcome in QoL at baseline and every 8 weeks. PARAGON's first objective is to determine the course of QoL throughout all applied therapy lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome. Secondary outcome measurements are e.g. progression-free, disease-free and overall survival according to treatment line.
Interventions
OTHERQuality of live questionnaires
EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
OTHEROptional translational project
Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
Sponsors
Celgene
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent and signed data protection form before any study specific intervention, including screening, will be done * Age ≥ 18 years * Histologically or cytologically confirmed pancreatic adenocarcinoma * Systemic neoadjuvant, adjuvant, 1st line systemic therapy is planned or recently started (within last 14 days)
Exclusion criteria
* Patients who are unable to consent because they do not understand the nature, significance and implications of the study * Patients who are unable to understand or fill out the QoL survey * Patients in 2nd or further treatment lines that have not been documented for 1st line therapy within the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The course of Quality of Life (QoL) throughout the entire course of therapy for patients with pancreatic adenocarcinoma | through study completion, an average of 1 year | EORTC-QLQC30 according to EORTC scoring manual |
| Other patient reported outcome (PRO) | through study completion, an average of 1 year | Physical performance status patient questionnaire according to ECOG criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression- free survival (PFS) | through study completion, an average of 1 year | As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures. |
| Disease-free survival (DFS) | through study completion, an average of 1 year | As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures. |
| Overall survival (OS) | through study completion, an average of 1 year | As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures. |
Countries
Germany
Outcome results
None listed